Recent Advances in CAR-T Therapy.

IF 2.5 4区医学 Q3 ONCOLOGY

Cancer Control Pub Date : 2024-01-01 DOI:10.1177/10732748241263713

Meher Binte Ali

引用次数: 0

Abstract

Chimeric antigen receptor T cell therapy is used to treat hematological malignancies which are refractory to standard therapy. It is a form of immunotherapy in which a patient's T cells are programmed to act against tumor cells. We discuss the process of manufacturing CAR-T cells, the common side effects of therapy, and the recent emerging risk of T-cell malignancies after treatment.

查看原文本刊更多论文

CAR-T 疗法的最新进展。

嵌合抗原受体 T 细胞疗法用于治疗对标准疗法难治的血液恶性肿瘤。它是一种免疫疗法，患者的 T 细胞经过编程后可对抗肿瘤细胞。我们将讨论 CAR-T 细胞的制造过程、治疗的常见副作用以及最近出现的治疗后 T 细胞恶性肿瘤的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Control ONCOLOGY-

CiteScore

3.80

自引率

0.00%

发文量

148

审稿时长

>12 weeks

期刊介绍： Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.

文献相关原料

公司名称	产品信息	采购帮参考价格